Acute Research centre (ARC) is a full service provider in basic chemistry research, API development of first to file (FTF) & future generics molecules, cost effective commercial technology of existing API and Intermediates, CRAMS, synthesis and characterization of analytical standards/impurities and regulatory expertise for global markets along with cGMP support services.. Expertise in the developments of cost effective novel technologies of API / Intermediates free from Genotoxtic impurities and quality benchmarking in identical with innovators. Our experience of more than 35 yrs with patents and several publications worldwide. ARC team brings a depth knowledge and breadth of experience across drug substance/product development pathways, allowing us to address the full scope of a client’s regulatory and drug substance development needs and closely worked with various regulatory authorities.

Acute Research: R&D-led API development, EU-GMP capable manufacturing, focused formulation portfolio and contract R&D services.

Research and development

Source: Ministry of Corporate Affairs company master (open data). Capital figures are as-of the 2021 registry snapshot, not live.

Extracted from Acute Research Private Limited's own website, fetched Jul 2026. Verification badges reflect format/MX checks, not endorsement.